Terms: = Prostate cancer AND CCND1, BCL1, 595, ENSG00000110092, PRAD1, U21B31, D11S287E AND Staging
4 results:
1. Pan-cancer analysis of prognostic metastatic phenotypes.
Zaorsky NG; Wang X; Garrett SM; Lehrer EJ; Lin C; DeGraff DJ; Spratt DE; Trifiletti DM; Kishan AU; Showalter TN; Park HS; Yang JT; Chinchilli VM; Wang M
Int J Cancer; 2022 Jan; 150(1):132-141. PubMed ID: 34287840
[TBL] [Abstract] [Full Text] [Related]
2. Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (
Bach-Gansmo T; Nanni C; Nieh PT; Zanoni L; Bogsrud TV; Sletten H; Korsan KA; Kieboom J; Tade FI; Odewole O; Chau A; Ward P; Goodman MM; Fanti S; Schuster DM; Willoch F
J Urol; 2017 Mar; 197(3 Pt 1):676-683. PubMed ID: 27746282
[TBL] [Abstract] [Full Text] [Related]
3. A comparison of arterial spin labeling perfusion MRI and DCE-MRI in human prostate cancer.
Cai W; Li F; Wang J; Du H; Wang X; Zhang J; Fang J; Jiang X
NMR Biomed; 2014 Jul; 27(7):817-25. PubMed ID: 24809332
[TBL] [Abstract] [Full Text] [Related]
4. Overview of benign and malignant prostatic disease in Pakistani patients: a clinical and histopathological perspective.
Arshad H; Ahmad Z
Asian Pac J Cancer Prev; 2013; 14(5):3005-10. PubMed ID: 23803070
[TBL] [Abstract] [Full Text] [Related]
